PT2254869T - Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40 - Google Patents

Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40

Info

Publication number
PT2254869T
PT2254869T PT97176382T PT09717638T PT2254869T PT 2254869 T PT2254869 T PT 2254869T PT 97176382 T PT97176382 T PT 97176382T PT 09717638 T PT09717638 T PT 09717638T PT 2254869 T PT2254869 T PT 2254869T
Authority
PT
Portugal
Prior art keywords
cx3cr1
benzyl
expression
novel
treatment
Prior art date
Application number
PT97176382T
Other languages
English (en)
Portuguese (pt)
Inventor
Guglielmotti Angelo
Furlotti Guido
Mangano Giorgina
Cazzolla Nicola
Garofalo Barbara
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of PT2254869T publication Critical patent/PT2254869T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
PT97176382T 2008-03-07 2009-03-05 Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40 PT2254869T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08425139 2008-03-07

Publications (1)

Publication Number Publication Date
PT2254869T true PT2254869T (pt) 2017-07-18

Family

ID=39671487

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97176382T PT2254869T (pt) 2008-03-07 2009-03-05 Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40

Country Status (25)

Country Link
US (3) US7919518B2 (OSRAM)
EP (3) EP3181551A1 (OSRAM)
JP (2) JP5509101B2 (OSRAM)
KR (2) KR101581828B1 (OSRAM)
CN (2) CN101952256B (OSRAM)
AR (2) AR070810A1 (OSRAM)
AU (2) AU2009221089B2 (OSRAM)
BR (2) BRPI0907976A2 (OSRAM)
CA (2) CA2712703C (OSRAM)
CY (2) CY1117584T1 (OSRAM)
DK (2) DK2254869T3 (OSRAM)
EA (2) EA018241B1 (OSRAM)
ES (2) ES2637009T3 (OSRAM)
GE (2) GEP20135912B (OSRAM)
HR (2) HRP20171208T1 (OSRAM)
HU (1) HUE027098T2 (OSRAM)
IL (3) IL206893A0 (OSRAM)
LT (1) LT2254869T (OSRAM)
MX (2) MX2010009623A (OSRAM)
PL (2) PL2254869T3 (OSRAM)
PT (1) PT2254869T (OSRAM)
SG (1) SG188177A1 (OSRAM)
SI (2) SI2254869T1 (OSRAM)
UA (2) UA103605C2 (OSRAM)
WO (2) WO2009109618A2 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5509102B2 (ja) 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な1−ベンジル−3−ヒドロキシメチルインダゾール誘導体およびそのmcp−1およびcx3cr1の発現に基づく疾患の治療への使用
LT2254869T (lt) * 2008-03-07 2017-08-10 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Nauji 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydyme ligų, susijusių su cx3cr1 ir p40 raiška
CA2714436C (en) * 2008-03-07 2017-06-27 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
PL2462119T3 (pl) * 2009-08-03 2014-10-31 Acraf Sposób wytwarzania 1-benzylo-3-hydroksymetylo-1H-indazolu i jego pochodnych oraz potrzebnych magnezowych związków pośrednich
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
CN104334173B (zh) * 2012-05-01 2017-05-03 特兰斯拉图姆医学公司 用于治疗和诊断致盲性眼病的方法
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
MX347615B (es) 2012-05-18 2017-05-04 Sanofi Sa Derivados de pirazol y su uso como antagonistas de lpar5.
US9346757B2 (en) 2012-05-18 2016-05-24 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
MX372807B (es) 2012-11-09 2020-07-03 Colgate Palmolive Co Copolimeros de bloque para proteccion del esmalte dental.
EP3142664B1 (en) * 2014-05-15 2019-12-04 Translatum Medicus Inc. Compositions and methods for treating and diagnosing ocular disorders
WO2016201426A1 (en) * 2015-06-12 2016-12-15 Vettore, LLC Mct4 inhibitors for treating disease
WO2016203313A1 (en) * 2015-06-16 2016-12-22 Translatum Medicus, Inc. Compositions and methods for treating and diagnosing ocular disorders
IL279949B2 (en) 2016-12-12 2025-03-01 Vettore Llc Heterocyclic MCT4 inhibitors
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
US11753382B2 (en) 2019-06-25 2023-09-12 Translatum Medicus Inc. Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
CN113929627A (zh) * 2021-10-19 2022-01-14 吕梁学院 一种宾达利的合成方法
WO2024108386A1 (zh) * 2022-11-22 2024-05-30 中国科学院深圳先进技术研究院 抗mcp1中和抗体在制备治疗神经退行性疾病引起的系统性炎症药物中的应用
WO2024165925A1 (en) * 2023-02-10 2024-08-15 Translatum Medicus Inc. Bindarit conjugates, compositions and methods for treating ocular diseases or disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US416359A (en) * 1889-12-03 Sash-fastener
US364371A (en) * 1887-06-07 peice
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1293795B1 (it) 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
WO2000078757A1 (en) 1999-06-17 2000-12-28 Shionogi Bioresearch Corp. Inhibitors of il-12 production
EP1199074A1 (en) 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
CA2440744C (en) 2001-03-15 2009-12-08 Seikagaku Corporation Il-12 expression controlling agent
CN100349876C (zh) 2001-11-30 2007-11-21 辛塔医药品有限公司 嘧啶化合物
JP2007507494A (ja) 2003-10-07 2007-03-29 アストラゼネカ・アクチエボラーグ ケモカイン受容体アンタゴニストとりわけCX3CR1として有用な新規な2−置換4−アミノ−チアゾロ[4,5−d]ピリミジン
ES2641815T3 (es) * 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
JP2008519850A (ja) 2004-11-10 2008-06-12 シンタ ファーマシューティカルズ コーポレーション Il−12調節化合物
EP1827447A1 (en) 2004-11-19 2007-09-05 Synta Pharmaceuticals Corporation Pyrimidine compounds and uses thereof
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
JP5509102B2 (ja) * 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な1−ベンジル−3−ヒドロキシメチルインダゾール誘導体およびそのmcp−1およびcx3cr1の発現に基づく疾患の治療への使用
CA2714436C (en) * 2008-03-07 2017-06-27 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
LT2254869T (lt) * 2008-03-07 2017-08-10 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Nauji 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydyme ligų, susijusių su cx3cr1 ir p40 raiška

Also Published As

Publication number Publication date
SG188177A1 (en) 2013-03-28
HRP20160462T1 (hr) 2016-06-03
CN101945855A (zh) 2011-01-12
LT2254869T (lt) 2017-08-10
WO2009109613A3 (en) 2009-12-10
UA105170C2 (en) 2014-04-25
BRPI0907977A2 (pt) 2015-08-04
CN101952256B (zh) 2016-03-16
US8283348B2 (en) 2012-10-09
DK2254870T3 (en) 2016-05-17
EP2254869B1 (en) 2017-05-31
JP2011513365A (ja) 2011-04-28
IL207131A0 (en) 2010-12-30
IL215579A (en) 2015-06-30
EP2254870B1 (en) 2016-02-24
EA201071040A1 (ru) 2011-02-28
IL206893A0 (en) 2010-12-30
CY1119252T1 (el) 2018-02-14
CA2712703A1 (en) 2009-09-11
PL2254870T3 (pl) 2016-07-29
GEP20135983B (en) 2013-12-10
ES2637009T3 (es) 2017-10-10
AU2009221089A1 (en) 2009-09-11
EA018241B1 (ru) 2013-06-28
JP5509099B2 (ja) 2014-06-04
IL207131A (en) 2013-02-28
EP3181551A1 (en) 2017-06-21
JP2011513367A (ja) 2011-04-28
US20110003874A1 (en) 2011-01-06
CA2712403A1 (en) 2009-09-11
JP5509101B2 (ja) 2014-06-04
SI2254869T1 (sl) 2017-10-30
SI2254870T1 (sl) 2016-05-31
AU2009221089B2 (en) 2013-12-05
EA201071038A1 (ru) 2011-02-28
EP2254870A2 (en) 2010-12-01
KR101599867B1 (ko) 2016-03-04
CY1117584T1 (el) 2017-04-26
HUE027098T2 (en) 2016-08-29
CN101952256A (zh) 2011-01-19
AU2009221083B2 (en) 2013-11-28
US20110160205A1 (en) 2011-06-30
AU2009221083A1 (en) 2009-09-11
US20100311744A1 (en) 2010-12-09
US8835481B2 (en) 2014-09-16
PL2254869T3 (pl) 2017-10-31
ES2569330T3 (es) 2016-05-10
DK2254869T3 (en) 2017-09-04
KR101581828B1 (ko) 2015-12-31
MX2010009626A (es) 2010-12-20
EA019711B1 (ru) 2014-05-30
AR070811A1 (es) 2010-05-05
US7919518B2 (en) 2011-04-05
WO2009109618A2 (en) 2009-09-11
EP2254869A2 (en) 2010-12-01
BRPI0907976A2 (pt) 2015-08-04
HRP20171208T1 (hr) 2017-10-06
AR070810A1 (es) 2010-05-05
KR20100131432A (ko) 2010-12-15
CA2712703C (en) 2016-10-11
UA103605C2 (en) 2013-11-11
KR20100133957A (ko) 2010-12-22
WO2009109618A3 (en) 2009-12-10
CN101945855B (zh) 2014-12-17
CA2712403C (en) 2017-06-06
GEP20135912B (en) 2013-08-26
WO2009109613A2 (en) 2009-09-11
MX2010009623A (es) 2010-09-28
IL215579A0 (en) 2011-11-30

Similar Documents

Publication Publication Date Title
PT2254869T (pt) Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40
IL207277A0 (en) Novel 1 - benzyl - 3 - hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp - 1, cx3cr1 and p40
SI2170848T1 (sl) Derivati pirazinona in njihova uporaba pri zdravljenju bolezni pljuč
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
EP2262777B8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1
IL210802A0 (en) Purin derivatives for use in the treatment of fab-related diseases
IL210757A0 (en) Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
IL210803A0 (en) Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
EP2219448A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
PL2148667T3 (pl) Stosowanie pochodnych cycloheksanoheksolu w leczeniu chorób oczu
ZA201108106B (en) Use of phthalimide derivatives in the treatment of diseases
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
HRP20151393T8 (hr) UPORABA BENZIDAMINA U LIJEČENJU BOLESTI KOJE SU p40-OVISNE
HK1145323A (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
PL2224934T3 (pl) Zastosowanie osteoblastów w leczeniu zapalnych chorób reumatycznych
ZA200909073B (en) Pyrazinone derivatives and their use in the treatment of lung diseases
IL202502A0 (en) Agents for the treatment of inflammatory diseases and methods of using same